Millennium, Bayer, Wyeth-Ayerst Research deal

The companies announced the discovery of the first genome-derived small molecule cancer drug candidate from their 1998 collaboration. The companies, which said they moved from gene discovery to a clinical candidate in less than 18 months, plan to start Phase I trials this year. Under the deal, MLNM will provide Bayer with 225 genes and their associated proteins as targets for drug discovery.

Separately, under the companies’ 1996 collaboration, MLNM received milestone payments from Wyeth-Ayerst Research triggered by the delivery of a preclinical antibacterial candidate and three additional antibacterial drug targets. ...